DIAMOND in nasopharyngeal carcinoma: Time to drop cisplatin?

The phase 3 DIAMOND trial conducted in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) reported comparable 3-year failure-free survival rates between a cisplatin-containing versus a cisplatin-free regimen with radiotherapy, in the backbone of induction, concurrent, and adjuvant anti-programmed death-1 (anti-PD-1) therapy.1 Reduced cisplatin-related emesis also improved quality of life. DIAMOND challenges the conventional dogma of concurrent cisplatin-radiotherapy in the treatment of LA-NPC.